GALE News Alert Galena Biopharma (GALE) 1.49 12/25/2014 16:4

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Galena Biopharma (GALE) 1.49 $GALE

Adam Feuerstein's 2014 Biotech Stock Report Card (No Grading on a Curve)
at The Street - Fri Dec 19, 8:02AM CST
Good calls: Vertex, InterMune, Chelsea, Galena, Exact Sciences. The bad calls: Avanir, Amarin, Exelixis and the bursting biotech stock bubble.
VRTX: 115.15 (+1.40), GALE: 1.49 (-0.02), EXAS: 27.60 (+0.39), ARIA: 6.81 (+0.15), MNKD: 5.68 (+0.18)

Nominees for Absolute Worst Bio-Technology CEOs of 2014 Are ...
at The Street - Mon Dec 15, 10:49AM CST
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
NWBO: 5.58 (+0.04), DNDN: 0.13 (-0.02), RTRX: 12.92 (+0.19), CYTR: 2.58 (+0.03), RPRX: 8.88 (+0.24), GALE: 1.49 (-0.02), AEGR: 21.59 (-0.27)

Galena Biopharma Presents HER2 Screening Data Including Preliminary Leica Bond Oracle(TM) Results From the Phase 3 NeuVax(TM) (nelipepimut-S) Clinical Trial at the 2014 San Antonio Breast Cancer Symposium (SABCS)
GlobeNewswire - Thu Dec 11, 7:55AM CST
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that initial immunohistochemistry (IHC) screening data from the NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) trial was presented at the 2014 San Antonio Breast Cancer Symposium (SABCS).
GALE: 1.49 (-0.02)

RedHill submits MAA for ondansetron
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 11:38AM CST

INSY: 41.52 (+0.51), TSRO: 36.80 (+0.57), HRTX: 9.75 (+0.02), RDHL: 12.22 (-0.13), GWPH: 68.08 (+1.82), OPK: 9.63 (+0.21), GALE: 1.49 (-0.02)

Galena: I Am Bullish, However, Nobody Has Paid Me For My Stance
Kanak Kanti De - at Seeking Alpha - Tue Dec 09, 7:32AM CST

GALE: 1.49 (-0.02)

Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Clinical Trial Data at the 56th American Society of Hematology (ASH) Annual Meeting & Exposition
GlobeNewswire - Mon Dec 08, 6:05AM CST
-- Phase 1 results demonstrate GALE-401 reduces platelet counts with tolerable safety profile
GALE: 1.49 (-0.02)

This is Incredibly Good News for Breast Cancer Survivors
Sean Williams, The Motley Fool - Motley Fool - Sat Dec 06, 11:08AM CST
Source: Komen Austin via Flickr . There are few, if any, medical diagnoses in life that are scarier than cancer. Based on data from the Centers for Disease Control and Prevention, cancer is now the second-leading cause of death in the United...
PFE: 31.42 (-0.03), GALE: 1.49 (-0.02)

Galena Biopharma to Present HER2 Screening Data From the Phase 3 NeuVax(TM) (nelipepimut-S) Clinical Trial at the 2014 San Antonio Breast Cancer Symposium (SABCS)
GlobeNewswire - Fri Dec 05, 6:05AM CST
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that initial immunohistochemistry (IHC) screening data from the NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) trial will be presented at the 2014 San Antonio Breast Cancer Symposium (SABCS). The IHC screening data identifies IHC HER2 1+ and 2+ patients to support the PRESENT study and a companion diagnostic for NeuVax. The conference is taking place December 9-13, 2014 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
GALE: 1.49 (-0.02)

InMed Pharma's Hiring of Tiberend Highlights Biotech Focus
ACCESSWIRE - Wed Dec 03, 9:32AM CST
WHITEFISH, MT / ACCESSWIRE / December 3, 2014 / Cannabis based medicine is being widely adopted as the next exciting special interest sector of the biotech community. With GW Pharmaceuticals plc (NASDAQ: GWPH) and others conducting clinical trials targeting important indications like cancer pain and arthritis, the data collected so far has suggested that cannabinoids could have far-reaching beneficial effects on the human body.
ADXS: 7.57 (+0.50), GWPH: 68.08 (+1.82), GALE: 1.49 (-0.02)

Why Galena Biopharma Inc. Stock Sank 13% in November
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 03, 7:00AM CST
GALE data by YCharts What: Shares of Galena Biopharma , a biopharmaceutical company focused on developing immunotherapies to treat cancer, sank 13% in November, based on data from S&P Capital IQ , following a weak earnings report and a...
GALE: 1.49 (-0.02)

Galena Biopharma Receives Notice of Allowance of U.S. Patent Application for GALE-401 (Anagrelide Controlled Release) Composition of Matter
GlobeNewswire - Tue Dec 02, 6:05AM CST
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application for GALE-401 composition of matter. GALE-401 is a controlled release formulation of anagrelide for use in reducing platelet counts in patients with Myeloproliferative Neoplasms (MPNs).
GALE: 1.49 (-0.02)

Galena Biopharma to Present GALE-401 (Anagrelide Controlled Release) Phase 1 Clinical Trial Data at the 56th American Society of Hematology (ASH) Annual Meeting & Exposition
GlobeNewswire - Mon Dec 01, 6:05AM CST
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that data from the Company's Phase 1 clinical trials of GALE-401, or Anagrelide Controlled Release, will be presented at the upcoming 56th American Society of Hematology (ASH) Annual Meeting & Exposition. The poster presentation will also include preliminary data from the ongoing GALE-401 Phase 2 trial in patients with elevated platelet counts due to myeloproliferative neoplasms (MPNs). The conference takes place December 5-9, 2014 at the Moscone Center in San Francisco, CA.
GALE: 1.49 (-0.02)

Galena Biopharma to Present at the Oppenheimer 25th Annual Healthcare Conference
GlobeNewswire - Tue Nov 25, 6:05AM CST
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the Oppenheimer 25th Annual Healthcare Conference. The presentation will take place on Wednesday, December 10, 2014 at 3:55 p.m. ET at the Crowne Plaza Hotel in New York.
GALE: 1.49 (-0.02)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 11:46AM CST

CIMT: 8.81 (unch), CLRB: 3.02 (-0.05), MPX: 8.00 (-0.03), FATE: 4.90 (+0.23), TTPH: 38.86 (+0.53), PHMD: 1.46 (-0.03), BIND: 5.73 (+0.06), AXPW: 1.00 (-0.04), CANF: 3.70 (+0.01), SYN: 1.46 (-0.07), RNA: 18.76 (+0.10), CLIR: 7.63 (+0.16), VSCI: 0.76 (-0.07), OCRX: 5.77 (+0.02), GALE: 1.49 (-0.02), REI: 10.95 (+0.22), OGEN: 0.90 (-0.07), PTP: 73.65 (-0.03), FPRX: 26.12 (+0.07)

Galena, Shunned by Wall Street, Forced to Seek Pricey Vulture Financing
at The Street - Mon Nov 24, 8:39AM CST
The scandal-ridden Galena, still under active SEC investigation, was unable to muster sufficient interest from institutional investors.
GALE: 1.49 (-0.02)

Galena Biopharma Announces Purchase Agreement for Up to $55.0 Million With Lincoln Park Capital Fund, LLC
GlobeNewswire - Thu Nov 20, 3:20PM CST
-- Initial Purchase of $5.0 Million at $2.00 per share, 9% higher than the market close as of November 18, 2014
GALE: 1.49 (-0.02)

Today In SA PRO: Wednesday, November 19
SA PRO Top Ideas - at Seeking Alpha - Thu Nov 20, 4:00AM CST
Top Idea: Magnetek by Dane Capital Management, LLC: Long / Micro-Cap / Electrical Equipment / GARP / Dividend Distribution / Buyside Author / 40% Upside Outstanding Performance Award Winner #1: Top Long idea on RCPT (Receptos) by Stephen...
MAG: 38.01 (+0.33), GALE: 1.49 (-0.02)

Wall Street Breakfast: Dollar General May Have To Divest 4,000+ Stores
Wall Street Breakfast - Seeking Alpha - Wed Nov 19, 5:30AM CST
Economy The Ebola epidemic in west Africa has led mining companies in the region to put expansion plans on hold, delaying the rollout of jobs meant for residents of the countries hardest hit by the virus. ArcelorMittal (NYSE: MT ) has delayed a...
BX: 34.01 (+0.05), KKR: 23.14 (+0.24), BSX: 13.13 (+0.07), JNJ: 104.59 (+0.31), PBR: 7.60 (-0.11), T: 33.96 (-0.07), DLTR: 69.86 (-0.20), APO: 23.33 (-0.09), SPY: 207.77 (+0.02), TRP: 48.79 (unch), GALE: 1.49 (-0.02), DG: 69.86 (+0.31), TMUS: 26.67 (+0.07), PGRE: 18.46 (-0.07), RIO: 45.02 (+0.13), FDO: 79.14 (-0.01), DISH: 72.63 (+0.54), MT: 11.08 (-0.09), GS: 195.89 (+0.39), OME: 10.00 (+0.09), QQQ: 104.30 (+0.09), VZ: 47.67 (unch), PETM: 81.16 (+0.03)

Galena completes enrollment in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 12:34PM CST

GALE: 1.49 (-0.02)

Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena Biopharma, and XOMA
PR Newswire - Tue Nov 18, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Geron Corporation (NASDAQ: GERN), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Galena Biopharma Inc. (NASDAQ: GALE), and XOMA Corporation (NASDAQ: XOMA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 17, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,647.75, up 0.07% and the NASDAQ Composite closed at 4,671.00, down 0.37%. The S&P 500 finished the session 0.07% higher at 2,041.32. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 781.08, up 0.49%, with the index advancing 9.06% in the previous three months. Register for your complimentary reports on these five stocks at:
DRNA: 16.23 (-0.23), GERN: 3.06 (+0.05), TKMR: 13.97 (+0.14), GALE: 1.49 (-0.02), XOMA: 3.68 (+0.11), EXEL: 1.29 (-0.01)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 258

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 42

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 266

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 234

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 44

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 77

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 121

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 279

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 0

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading

Top 5 Most Recently Viewed Articles

Greenlight Re's Q3 2025: Underwriting Income Hits New Highs

Updated Category News Views 174

Greenlight Re's Impressive Financial Highlights Greenlight Capital Re, Ltd. (NASDAQ: GLRE) has made significant strides in its financial performance for the third quarter of 2025. The company has reported record underwriting income with a stellar combined ratio, making it a noteworthy player in the reinsurance industry. Strong Premium Growth In the third quarter of 2025,...

Continue Reading
Essential Insights into Recent Product Safety Recalls

Updated Category News Views 205

Understanding Recent Product Safety Recalls The U.S. Consumer Product Safety Commission (CPSC) plays a crucial role in safeguarding the public against injuries linked to consumer products. This article outlines significant recent recalls, the potential risks they pose, and what consumers should know to stay safe. Product Safety Recalls Overview The CPSC has identified...

Continue Reading
Famous Brands Launches New Dual Concept Store in Charlotte

Updated Category News Views 195

Famous Brands International Celebrates New Store Opening Famous Brands International recently marked a significant milestone with the grand opening of its latest co-branded store featuring iconic dessert brands Mrs. Fields and TCBY. This new establishment can be found nestled in a bustling shopping destination, engaging the community and sweetening up the offering for...

Continue Reading
Electric Vehicle Market Poised for Remarkable Growth Ahead

Updated Category News Views 177

Exploring the Future of the Electric Vehicle Market The electric vehicle (EV) market is on the brink of significant growth, driven by heightened global awareness surrounding climate change and the necessity to reduce carbon emissions. The market's anticipated expansion is reflective of a broader shift in transportation preferences, as more consumers seek eco-friendly...

Continue Reading
Curis Secures $12.1 Million Through Direct Stock Offering

Updated Category News Views 29

Curis Completes Significant Capital Raise of $12.1 Million Curis, Inc. (NASDAQ: CRIS), a dedicated biotechnology company focusing on innovative therapies, recently revealed a significant financial endeavor. The company is raising $12.1 million through a registered direct offering and a concurrent private placement. This strategic move enables Curis to bolster its ongoing...

Continue Reading